Related Experiment Video
Updated: Sep 7, 2026

Optimized Protocol for the Extraction of Proteins from the Human Mitral Valve
Published on: June 14, 2017
Circulating Biomarkers Related to Mitral Valve Prolapse: Current Evidence and Mechanistic Perspective
Liana Maries1,2, Thammarak Songsangjinda1,3, Dipan J Shah4
1Houston Methodist DeBakey Heart & Vascular Center, 6550 Fannin, Suite 1801, Houston, TX, 77030, USA.
Purpose Of Review:
Although imaging remains central to diagnosis and risk stratification, circulating biomarkers provide complementary information reflecting myocardial stress, fibrosis, extracellular matrix remodeling, inflammation, and metabolic dysregulation. The purpose of this review is to critically evaluate current and emerging circulating biomarkers in MVP and to assess whether these biomarkers may improve individualized management of this disease.
Recent Findings:
Natriuretic peptides are the most validated biomarkers in MVP, consistently predicting adverse outcomes and providing complementary prognostic information that may help inform the timing of surgical intervention, particularly in asymptomatic patients with significant mitral regurgitation. In contrast, evidence supporting fibrosis and inflammation mediators, proteomics, metabolomics, and circulating microRNAs remains emerging. In arrhythmic MVP, no circulating biomarker is currently recommended for routine risk stratification. Future research should prioritize phenotype-specific MVP registries, biomarker-CMR integration, multi-omics profiling, and biomarker-guided interventional trials.
More Related Videos
Related Concept Videos
Mitral Valve Prolapse I: Introduction
Mitral Valve Prolapse II: Assessment and Management
Mitral Regurgitation II: Clinical Features and Diagnostic Tests
Mitral Stenosis II: Clinical features and Diagnostic Tests
Mitral Regurgitation I: Introduction
Mitral Regurgitation III: Medical Management

